Interesting announcement from Respiri (RSH) yesterday.
"WHEEZOS IN CHINESE HOSPITALS
Respiri Ltd (RSH) has agreed to a request by three hospitals in China to trial Wheezo's on patients admitted with heightened respiratory problems resulting from infection with the coronavirus COVID19.
Three hospitals under the supervision of the Chongqing Municipal Health Commission have expressed their interest in using Respiri's wheezo device to help monitor the lung function of patients who have been admitted with the COVID19 virus."
Respiri's "Wheezo" can objectively monitor an Asthma or COPD patients wheeze (main symptom of asthma) + combines that with an app providing the full life cycle of patient data (symptoms, triggers, medication, environmental conditions) to provide the perfect complimentary tool for patients in between doctor and hospital visits.
Coronavirus just like the common cold acts as a trigger for an asthmatics asthma - as such the current environment requires extra caution from asthmatics globally.
Today also the WHO and CDC highlighted the risk from COVID19 for people with chronic health conditions such as - Asthma - Blood pressure / heart disease - Diabetes
The interesting thing about this list above is Asthma is the only one which doesn't have objective digital based symptom monitors widely available to patients - It could be the perfect time for Respiri to launch its Wheezo product in Q4 this year.
